ArticleBiotechnologia2025
Bioinformatics study of biotin carboxylase B-subdomain isolated from
Article in Biotechnologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing threat of antibiotic-resistant bacteria is a significant global health concern, with millions of people worldwide infected with these resistant strains each year. This study aims to conduct a bioinformatics analysis to investigate the biotin carboxylase (BC) B-subdomain from Materials and methods: Whole-genome sequencing data of Lac3, generated using the Illumina MiSeq sequencer (Novogene Co., Ltd.), were used to analyze gene clusters with AntiSMASH. Molecular docking (PyRx Virtual Screening Tool; AutoDock Vina) and molecular dynamics simulations (CPPTRAJ software) were performed to elucidate the potential binding sites of the BC B-subdomain and compare them with the BC domain from a Results: Bioinformatics analysis showed that the BC B-subdomain gene was located in the β-lactone gene cluster on contig 7.1 and consisted of 32.1% α-helix, 37.6% β-strand, and 24.8% random coil. Physicochemical analysis indicated that the BC B-subdomain protein exhibited a high degree of solubility. The BC B-subdomain shared similarities with the ATP-grasp domain of the BC domain from the reference strain, particularly in amino acid residues involved in ATP binding (His207, Gln231, Asn234, and Glu274). Molecular docking analysis demonstrated that the BC B-subdomain-ATP complex (-6.1 kcal/mol) was comparable to the BC domain-ATP complex (-8.8 kcal/mol). This was supported by molecular dynamics simulations, which indicated that the complex models remained stable throughout the simulations, based on several validation parameters, including RMSD, RMSF, Rg, and SASA. Furthermore, ionic interactions with the phosphate group's amino acid residues - critical for ATP binding and function within ATP-grasp enzymes - were observed in both the BC B-subdomain (His207 and Lys236) and the BC domain (Lys236 and Arg290). Conclusions: These findings suggest that the BC B-subdomain could serve as a potential target for fragment-based drug discovery and may provide a reference for developing novel BC inhibitors with potent antibacterial activity by targeting ATP binding, possibly through its phosphate group binding sites. However, further analysis is needed to support the development of innovative antibacterial treatments in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.